>100 >25 >20 New product launches expected by FY25 New products with potential to generate $ 50m+ per year 4 New products with potential to generate $ 30m – $50m per year 4 Innovation at BD Research and development BD conducts its research and development (R&D) activities at its operating units and across global enterprise centers of excellence located in the United States, India, China, Singapore and Ireland. The majority of BD’s R&D activities are conducted in North America. BD also collaborates with certain universities, medical centers and other entities on R&D programs and retains individual consultants and partners to support its efforts in specialized fields. Management highlights In April 2021 , we announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer. She is responsible for driving the company’s category innovation strategy and leading all R&D activities, including executing the current innovation pipeline and developing the future product portfolio. In April 2021, we also announced the creation of an external Scientific Advisory Board (SAB), which will comprise key top medical opinion leaders, science and technology experts and experienced innovation leaders. The SAB will review BD’s technology capabilities, innovation pipeline, tuck-in M&A (merger and acquisition) opportunities and early-stage investments. The SAB will also advise BD’s leadership on its growth prioritization as well as emerging trends in healthcare, science and technology, and the potential implications for BD. John DeFord, who retired as chief technology officer in May 2021, is the founding member and co-chair of the SAB. The SAB is also co-chaired by BD’s senior vice president and chief scientific officer, Dr. Joseph M. Smith, who joined BD in November 2021 . As chief scientific officer, Dr. Smith is primarily responsible for external innovation and BD’s technology roadmap to deliver transformative innovations. BD announced the inaugural members of the SAB in May 2022 . R&D initiatives In December 2021, we announced plans to invest €70 million over five years in BD’s Research Centre Ireland R&D Centre of Excellence in Limerick. This investment will further position the facility as a hub for the development of smart, secure and connected health and infection monitoring solutions in clinical and nonclinical settings. As a result, BD will add approximately 130 new, high-quality research and development positions in engineering and scientific disciplines such as software, electronics, hardware and immunology. The expansion of the facility will include a state-of- the-art laboratory, workspaces and technologies to support cutting-edge innovation. This project is supported by the Irish Government through IDA Ireland. 4 Revenues are based on estimated fifth-year sales post launch, which may occur after FY25. 13 2021 ESG Report Appendices Transparency Healthy workforce and communities Responsible supply chain Product impact Climate change Introduction